Search company, investor...


Founded Year



Debt - III | Alive

Total Raised


Last Raised

$2.45M | 10 yrs ago

About Allozyne

Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.

Headquarters Location

999 Third Ave Suite 3400

Seattle, Washington, 98104,

United States


Missing: Allozyne's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Allozyne's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Allozyne

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Allozyne is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Allozyne Patents

Allozyne has filed 6 patents.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Proteins, Amino acids, Protein domains, Gene expression


Application Date


Grant Date



Related Topics

Molecular biology, Proteins, Amino acids, Protein domains, Gene expression



Latest Allozyne News

Q3 In Review: Microsoft, Life Sciences Roller Coaster, UW Startups

Sep 30, 2014

Rounding out the top biotech stories was Lash’s exclusive report on the fate of Accelerator graduate Allozyne : Its assets and intellectual property were sold to MedImmune, a unit of AstraZeneca. Also, see Fidler’s in-depth Q&A with new Accelerator CEO Thong Le on expanding to New York . I spent much of the summer getting deep into the University of Washington’s technology transfer operation as it goes through a major transition in funding, leadership, and goals . The Center for Commercialization still aims to drive new startup formation, but I found that the way it and other university technology transfer shops count their output falls well short of clearly communicating the economic impact of their work. For example, startups that receive significant assistance from the UW, but aren’t based on university-licensed intellectual property, aren’t counted as UW startup companies. GraphLab, which was incubated in the UW’s New Ventures Facility and this summer moved to a larger office to accommodate its growing staff, is one such company. I took a look at GraphLab’s first commercial product—tools for developing scalable, data-centric, predictive applications . Benjamin Romano is editor of Xconomy Seattle. Email him at bromano [at] Follow @bromano Share or Leave a Comment

Allozyne Frequently Asked Questions (FAQ)

  • When was Allozyne founded?

    Allozyne was founded in 2005.

  • Where is Allozyne's headquarters?

    Allozyne's headquarters is located at 999 Third Ave, Seattle.

  • What is Allozyne's latest funding round?

    Allozyne's latest funding round is Debt - III.

  • How much did Allozyne raise?

    Allozyne raised a total of $40.45M.

  • Who are the investors of Allozyne?

    Investors of Allozyne include ARCH Venture Partners, OVP Venture Partners, Clarus, Amgen Ventures, Alexandria Venture Investments and 5 more.

  • Who are Allozyne's competitors?

    Competitors of Allozyne include Armgo Pharma, Flexion Therapeutics, Amplyx Pharmaceuticals, GenScript, Receptos and 13 more.

Compare Allozyne to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Cogentus Pharmaceuticals

Cogentus Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006. Cogentus is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.


QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

Cerevast Therapeutics

Cerevast Therapeutics is developing a non-invasive treatment for acute ischemic stroke known as sonothrombolysis, or SonoLysis for short. This treatment harnesses the acoustic energy from externally applied ultrasound to treat stroke-causing clots in the blood vessels of the brain. The company has developed an operator-independent ultrasonic headframe called the ClotBust-ER. This device can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.